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ABSTRACT
Objectives: Drug safety and postmarketing surveillance have
become important public health issues in China. This study
reviews the relatively new drug safety surveillance system in
China and compares it with the systems in the United States
and Europe.
Methods: An extensive literature review was conducted in
the following four areas: 1) the organizational structure of
the State Food and Drug Administration (SFDA) in China;
2) the development of an adverse drug reaction (ADR) moni-
toring system in China; 3) regulatory issues related to drug
safety in China; and 4) similarities and differences between
drug safety surveillance in China and surveillance in the
United States and Europe.
Results: The SFDA oversees an extensive network of drug
safety “watchdogs,” including the China National Center for
ADR Monitoring and 32 regional centers throughout China.
China’s system has faced a number of recent challenges. It
has had to respond quickly to the withdrawal of various
high-proﬁle drugs like Vioxx (rofecoxib) and Baycol (ceriva-
statin) from other markets. Together with China’s Ministry
of Health, the SFDA has faced several unique drug safety
events. Three of those events, involving the injectable form of
the heartleaf houttuyinia herb (Yu Xing Cao), Armillarisni A
injections, and clindamycin glucose infusions (Xinfu), are
discussed. The rapid development of drug safety surveillance
in China is manifested in extensive organizational structure,
development of large databases, and laws and regulations
supporting drug safety. The two major laws are the China
Drug Administration Law issued in February 2001 and the
Regulation for the Administration of ADR Reporting and
Monitoring issued in March 2004. The study also discusses
and compares recent developments in drug safety surveillance
in the United States and the European Union. These devel-
opments will most likely have implications for the Chinese
system in the near future.
Conclusions: While postmarketing surveillance guidelines
are not yet available in China, we fully expect their eventual
issuance after adaptation to the particular culture and clinical
practices in China.
Keywords: adverse drug reaction, China, drug safety,
surveillance.
Introduction
Just as China’s economy grows and develops at a very
fast pace, its system for watching over drug safety is
evolving very quickly as well. Whereas two decades
ago, it would have been next to impossible to identify a
noncentralized safety problem, nowadays, the national
drug safety system, headed by the State Food and Drug
Administration (SFDA) is quite likely to identify it,
investigate it, and solve it. Although patterned loosely
after more developed systems, like the system involving
the Food and Drug Administration (FDA) in the United
States, the Chinese system has some unique features,
stemming partly from its very large 1.3 billion popula-
tion, its extreme regional demographic disparities, and
different clinical practices. The system has already been
tested heavily. Shortly after several high-proﬁle phar-
maceuticals like Vioxx (rofecoxib), Baycol (cerivasta-
tin), and Propusid (cisapride) were withdrawn from the
USmarket, the SFDAwas able to react quickly by either
issuing a drug-use warning or withdrawing the drug
from the Chinese market as well. Moreover, it has faced
several challenges within its own borders. In this review
article, we ﬁrst describe the Chinese system for drug
safety surveillance, which relies strongly on the adverse
drug reaction (ADR) reporting and monitoring system
and some major Chinese drug-safety regulations. We
also describe the system’s response to three drug safety
events, one involving a traditional Chinese medicine
(TCM), the heartleaf houttuynia herb, one involving
the Armillarisni A injection, and the third involving
clindamycin glucose infusions.We conclude by compar-
ing the Chinese system with drug safety frameworks in
the United States and the European Union.
Because the Chinese system is so new, there is no
scholarly literature as yet on the economics of
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improved drug safety in China. However, in the United
States, where a longer surveillance history exists, drug-
related morbidity and mortality are major patient
safety issues that have an estimated US$177.4 billion
annual cost because of treatment failures and new
medical problems they generate [1]. The overall inci-
dence of serious and fatal ADRs in US hospitals is
estimated to be 6.7% and 0.32% of hospitalized
patients, respectively [2]. This estimation implies
76,000–137,000 fatal ADRs each year in the mid-
1990s, making ADR mortality the sixth leading cause
of death in the United States. By the time that Vioxx®
was withdrawn from the market in September 2004,
the number of people who suffered heart attacks,
strokes, and blood clots (often with signiﬁcant health
care costs and resource utilization) because of the drug
was estimated to be over 100,000 [3]. Hence, improve-
ments in either the ADR reporting system or in the
techniques used to screen ADRs are expected to lead to
signiﬁcant improvements in clinical as well as eco-
nomic outcomes in any country.
The National Center for Adverse Drug
Reaction Monitoring
At the foundation of China’s drug safety surveillance
program is its National Center for ADR Monitoring.
As early as 1988, the national ADR monitoring project
was initiated with the support of the China Ministry
of Health (MOH), and involved 10 regional medical
organizations within several cities and provinces,
including Beijing, Shanghai, Hubei, Heilongjiang, and
other provinces [4,5]. In late 1989, the National
Center for ADR Monitoring was formally established
and primarily focused on 85 hospitals nationwide that
were responsible for monitoring ADR events [4,5]. In
1998, the National Center joined the World Health
Organization’s Collaborating Center for International
Drug Monitoring (called the Uppsala Monitoring
Center) [4,5]. In 1999, the National Center for ADR
Monitoring which also houses the Center for Drug
Reevaluation (CDR) joined the SFDA and reports to
both the SFDA and the MOH. The National Center
consists of ﬁve divisions and has a network of 32
provincial centers for ADR monitoring that are afﬁli-
ated with local SFDA ofﬁces in different provinces,
autonomous regions, and municipal governments [6].
Individuals may ﬁle an ADR or Adverse Drug Event
(ADE) report either directly with the National Center
or through one of the regional centers. Hospitals, drug
distributors, pharmacies, and pharmaceutical compa-
nies, on the other hand, submit ADR/ADE reports to
regional centers (see Fig. 1). It is the responsibility of
the regional center to report all new ADRs/ADEs and
all serious ADRs/ADEs within three days to the
National Center. Other ADR/ADE reports are sent
from the regional centers to the National Center on a
quarterly basis. The Internet is used for the ﬁling of
all reports, and advanced information technology
supports the system. Whereas the National Center
received a total of 4700 reports in the 11 years from
1988 through 1999, it received 17,000 in the year
2002 alone, and an incredible 173,000 in 2005 (see
Fig. 2) [4,7]. The system is clearly now receiving heavy
use. This spontaneous reporting system can be used by
any alert physician or other health care professional
who thinks that a disease, symptom, or disorder might
be related to the use of a particular drug.
As ADR/ADE reports are collected by the system,
their nature and frequency can help uncover problems
with marketed drugs, especially new drugs. While the
system is used—as we discuss below—to detect and
conﬁrm rather rare cases of ADRs not detected during
pre-marketing testing, it also provides a signiﬁcant
amount of data for researchers to test general hypoth-
eses concerning pharmaceutical safety. Of course, the
easy-to-use, inexpensive spontaneous reporting system
has its limitations. The number of ADR/ADE reports
alone does not provide an ADR/ADE incidence rate,
because we do not generally know the number of
people exposed to a speciﬁc drug. Moreover, the infor-
mation on the ADR/ADE reports may have inaccura-
cies and omissions. Finally, even with the large number
of reports being submitted, it is still probably the case
that signiﬁcant under-reporting is still occurring in
some parts of China.
The ADR/ADE reporting system covers both ADRs
and ADEs. According to the International Conference
on Harmonization (ICH), an ADR is deﬁned as “a
response to a drug which is noxious and unintended
and which occurs at doses normally used in man for
prophylaxis, diagnosis, or therapy of disease or for
the modiﬁcation of physiologic function [8].” On the
other hand, an ADE is deﬁned as “any untoward
medical occurrence that may present during treatment
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Figure 1 Structure and procedures for the ADR monitoring and report-
ing network in China [1–3].
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with a pharmaceutical product but which does not
necessarily have a causal relationship with this treat-
ment [8].” According to the deﬁnitions, the concept of
an ADR is an ADE with a causal link to a drug.
Both western medicines and TCMs are covered by
the ADR/ADE reporting system and are regulated by
the SFDA. However, although information from the
FDA or the European Medicines Agency (EMeA) is
available for western medicines to help guide SFDA
policy, the SFDA must be more creative in its regula-
tion of TCMs. According to the Chinese Medical Insti-
tute & Register, growing demand for TCMs in western
countries has put the spotlight on education, proper
practice, and safety to facilitate the integration of
TCMs and western medical practice [9].
Drug Safety Regulations and Requirements
The fundamental legal document governing the admin-
istration of the pharmaceutical industry in China is the
“Drug Administration Law of the People’s Republic of
China” (“The Law”) issued in February 2001 [10].
Chapter 5 of The Law contains the mandate for drug
safety surveillance [10].
Based on The Law, there are several speciﬁc regu-
lations focused on drug safety surveillance in China.
The most important one is the “Regulation for the
Administration of Adverse Drug Reaction Reporting
and Monitoring,” which was issued jointly by the
SFDA and the MOH in 1999, and revised and dissemi-
nated in March 2004 [4,11]. This regulation includes
administrative responsibilities, reporting procedures,
and measures for evaluation and control [11]. It also
lists the penalties for not following these regulations
and provides the basis for establishing the provincial-
level regional ADR centers. The Regulation requires
pharmaceutical companies, distributors, pharmacies,
and medical organizations to monitor and report all
ADRs/ADEs. For any new or serious ADE, the desig-
nated staff has 15 days to report it to the regional
center. All other events must be submitted on a quar-
terly basis. Deadly ADRs/ADEs must be reported
immediately to the provincial monitoring center, which
is then required to investigate and verify the event, as
well as report it to the National Center within three
days. Those reports should be accompanied by sugges-
tions for follow-up action.
The “Regulation for the Administration of Adverse
Drug Reaction Reporting and Monitoring” requires
the National Center to compile statistical data on all
ADRs/ADEs for the SFDA and the MOH every six
months. The National Center also periodically orga-
nizes scientiﬁc research or initiates pharmacoepide-
miologic studies on particular drug therapies.
Additionally, the National Center is required to inves-
tigate, analyze, and evaluate quickly, for the SFDA and
the MOH, any new, serious, or uncommon ADR/ADE.
Besides the Regulation, there are several other regu-
lations that support drug safety surveillance in China,
such as “Provisions for Chinese Traditional Medicines
Administration of the People’s Republic of China,”
“Provisions for Quality Control for Pharmaceutical
Manufacturing,” and “Provisions for Quality Control
for Clinical Trials,” among others [12]. Other types of
regulations are being discussed as well. For example,
regulations for post-marketing evaluation have been
discussed recently in the CDR [13]. The post-
marketing drug evaluations might focus on drug safety
and effectiveness for recently approved new chemical
entities.
Publications and Media
Good communication between the government and
the public regarding drug safety is critical. For the
system to be successful, doctors, pharmacists, and
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patients need to feel conﬁdent that the government is
reacting quickly and appropriately to any ADR/ADE
emergency. On its side, the government must balance
its concern over the health of its citizens with the
importance of a thorough investigation so as not to
place any blame too quickly and frighten individuals
needlessly. In order to facilitate communication with
the public about drug safety, the National Center for
ADR Monitoring launched its Web pages http://
www.cdr.gov.cn and http://www.adr.gov.cn [6,14].
These Web sites are the most active media for drug
label changes and warnings, and are used as well for
conducting nationwide questionnaire surveys on drug
safety surveillance. Moreover, the National Center has
two publications including the ADR Information Bul-
letin and the Chinese Journal of Pharmacovigilance.
The Bulletin, which has been available to the public
since 2001, announces the ADR/ADE reports involv-
ing serious injury or fatalities. Some warnings and
safety signals generated by analysis of the national
ADR database have been published in the Bulletin.
The Bulletin covers western pharmaceutical products
and TCMs, as well as different formulations (oral and
injectable) of drugs. The Chinese Journal of Pharma-
covigilance is an academic journal covering a wide
range of drug safety issues including ofﬁcial regula-
tions about drug safety; vaccine safety; medical device
safety; new developments in drug safety research, and
pharmacovigilance; current developments and issues in
international pharmacovigilance; and post-marketing
surveillance in the pharmaceutical industry and the
medical-device industry.
Recent Drug Safety Events in China
China’s system for ensuring drug safety has faced
several big, unique tests in recent years. The ﬁrst chal-
lenge described in this section came from a TCM:
heartleaf houttuynia herb (Yu Xing Cao) which has
been orally administered in China for more than
2000 years [15,16]. In the 1980s, however, injectable
formulations of the heartleaf houttuynia herb were
approved by the SFDA, and because of their cheap
prices and rapid effect, became widely used in clinical
practice for infections. From 1988 to 2003, the
National Center for ADR Monitoring received 272
ADR/ADE reports, 52 of which were for severe ADRs/
ADEs, related to its injection [17–19]. In August 2003,
the National Center issued a warning letter to health
professionals [18]. Then, on June 1, 2006, the SFDA
temporarily withdrew all seven injectable forms of the
heartleaf houttuynia herb from the market [20]. After
a three-month evaluation, the SFDA decided to let the
injection return to the market step by step with risk-
management (e.g., collecting ADR/ADE reports and
alerting clinicians about appropriate use) [21]. In
addition, production of the heartleaf houttuynia herb
must follow strict requirements.
Another unique drug safety event threatened the
Chinese people in the summer of 2006. After receiving
injections of clindamycin phosphate glucose, many
people were becoming violently ill with multiple symp-
toms including chest distress, abdominal pain, pain in
the kidney, diarrhea, nausea, vomiting, and anaphylac-
tic shock [22]. More than 100 severe ADRs/ADEs,
including nine fatalities, across 15 provinces, were
reported to the National Center for ADR Monitoring
[22,23]. On July 27, just three days after the ﬁrst
suspected fatal case, the SFDA posted an ADR
warning for the clindamycin injection on its Web site.
After a preliminary investigation, the SFDA asked for
a nationwide recall of the injections on August 4 [24].
Soon it was found that a single brand of clindamycin,
Xinfu, produced by the Anhui Huayuan Company,
was responsible for the ADEs. The ADEs were caused
by bacterial infections during production. Throughout
the investigation process, the MOH worked closely
with the SFDA to develop guidance for physicians and
hospitals regarding treatment of patients reacting to
the Xinfu injection. On August 3, the MOH activated
its emergency daily reporting system—last used during
the severe acute respiratory syndrome (SARS) out-
break in China—in 2003 [24].
Overall, the handling of the Xinfu disaster was an
impressive performance for the ﬂedgling Chinese ADR
reporting system. Nevertheless, the Xinfu clindamycin
event also provided a wake up call for the government
to try to reduce prescription antibiotic drug abuse in
China, as well as the overuse of riskier intravenous
formulations of antibiotics. Moreover, it is very clear
that the Chinese government still has signiﬁcant work
to do regarding safe manufacturing practices. The
Anhui Huayuan Pharmacy Company is not the ﬁrst
company to violate Good Manufacturing Practice
standards. In fact, in Spring 2006, shortly before the
Xinfu events, at least 11 people fell ill and ﬁve people
died after taking an injection of Armillarisni A (a drug
used to treat gall bladder, liver, and gastric disorders)
made by Qiqihar No. 2 Pharmaceutical Co. in China’s
Heilongjiang Province [25]. The drug company used
diglycol instead of propylene glycol for the production
of the Armillarisni A in September 2005. Diglycol
caused acute kidney failure for patients taking Armill-
arisni A. The disaster caused a national outcry and
prompted the government to shut down the Qiqihar
Company.
Drug Safety Surveillance in the United States
and the European Union
Because the SFDA in China looks to the United States
and Europe and other developed countries for features
of their drug-safety systems that are worth adopting, it
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is important to review drug safety in these countries in
order to predict future development of the system in
China. However, doing so is not an easy task, because
systems in the United States and Europe are continu-
ally evolving themselves in response to new problems
that challenge the systems’ abilities. In the past decade,
for example, more than a dozen high-proﬁle drugs,
including rofecoxib (Vioxx), cisapride (Propulsid), tro-
glization (Rezulin), terfenadine (Seldane), and cerivas-
tatin (Baycol), were withdrawn from the market. In
response to so many withdrawals, pressure has been
building to reform drug safety regulations, and there
have been signiﬁcant developments in both the United
States and the European Union (E.U).
Recent Developments in the United States
Under the Prescription Drug User Fee Act, ﬁrst enacted
by the Congress in 1992 and revised in 1997 and 2002,
the FDA has been charged with developing risk-
management guidance for the pharmaceutical industry.
In March 2005, three separate guidances were issued
by the FDA including 1) Premarketing Risk Assess-
ment; 2) Development and Use of Risk Minimization
Action Plans (RiskMAP); and 3) Good Pharmacovigi-
lance Practices and Pharmacoepidemiologic Assess-
ment [26]. According to the Guidance for Industry,
drug safety risk-management is deﬁned as “an iterative
process designed to optimize the beneﬁt-risk balance
for regulated products [27]” and RiskMAP as “a stra-
tegic safety program designed to meet speciﬁc goals
and objectives in minimizing known risks of a product
while preserving its beneﬁts [28].” A variety of
RiskMAP tools are currently used in risk minimization
plans, such as targeted education and outreach, and
reminder systems that prompt, remind, double-check
or otherwise guide health care practitioners and/or
patients in prescribing, dispensing, receiving, or using
a product in ways that minimize risk. The FDA Guid-
ance requires companies to identify and describe drug
safety signals, to investigate signals beyond case
review, and to interpret signals in terms of risk. The
Guidance also speciﬁes the pharmacoepidemiologic
research methods that are commonly used for risk
assessment. In addition, the Guidance discusses how
important it is to develop disease and drug registries as
well as conduct patient or health provider surveys for
drug safety surveillance [29].
Recent Developments in the European Union
In November 2005, eight months after the US FDA
issued its Industry Guidance, the EMeA issued its risk-
management guideline [30]. The Guideline is based on
E.U. regulations for marketing authorization applica-
tions and marketing authorization holders. The EMeA
deﬁnes drug safety risk-management as “a set of phar-
macovigilance activities and interventions designed to
proactively identify, characterize, prevent or minimize
risks relating to medicinal products, including risk
communication and the assessment of the effectiveness
of risk minimization interventions.” The Guideline
includes at least three major components: drug safety
speciﬁcations, a risk minimization plan (RMP), and
risk minimization tools.
The E.U. Guideline follows the ICH and requires
safety speciﬁcations to include both non-clinical and
clinical elements [30]. Nonclinical speciﬁcation ele-
ments are toxicity, general pharmacology (e.g., QT
interval prolongation), and drug interactions. Ele-
ments for clinical speciﬁcation involve limitations of
clinical trial safety data, postmarketing exposure,
populations not studied, identiﬁed and potential
ADRs/ADEs, disease epidemiology, potential medica-
tion error, and class effects. The RMP requires that
pharmaceutical companies collect drug safety data
once a drug is marketed in order to identify safety risks
and beneﬁts. The EU-RMP activity includes signal
detection, adverse reaction reporting, periodic utiliza-
tion reports, and pharmacoepidemiological studies.
The EU-RMP is needed primarily for newly marketed
products. It is useful as well when there are signiﬁ-
cant changes to marketing authorization with a new
dosage form, a new route of administration, or new
indications/patient populations. To protect public
health and reduce the burden of ADRs/ADEs, the
Guideline discusses risk minimization tools that might
effectively reduce risk for patients and/or populations,
including label changes, warnings, educational pro-
grams for health care professionals and the public,
such as letters, a physician’s guide to prescribing, a
pharmacist’s guide to dispensing, patient information
brochures, patient registries, informed consent, and so
on.
AThree-Way Comparison
Whereas the United States and the E.U. have recently
issued risk-management guidelines, China is not quite
there yet. Moreover, in many other respects, the
Chinese system has yet to issue guidelines for the phar-
maceutical industry in areas such as the initiation of
safety surveillance, in government-industry communi-
cation, in the assessment of ADRs/ADEs, and in ﬁling
a new drug application. These results are summarized
in Table 1. China’s SFDA may work shortly to develop
guidelines similar to those in the western countries.
Any guidelines should utilize both prescriptive and
predictive approaches. The prescriptive approach to
drug safety surveillance assesses the beneﬁts and risks
throughout the drug’s life cycle, from discovery
through postmarketing surveillance. The predictive
approach develops strategies and regulations that
could prevent or minimize risks.
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Implications and Conclusion
There is no gold standard for a drug safety surveillance
system. Variations in culture and clinical practice
across countries make it impossible for China to
simply adopt another country’s practices without
modiﬁcation. However, what the China’s SFDA has
been doing and will continue to do is, ﬁrst, learn from
its own unique challenges, as it was forced to do with
Yu Xing Cao and Xinfu. These drug safety events were
unique to China, and it was up to China’s relatively
new system to handle the crises. Second, China does
have some well-developed systems in other countries
that it can try to mimic, to the extent that it makes
sense. It can watch the new developments across the
globe to ﬁnd best practices for application. In particu-
lar, both the United States and the E.U. have recently
issued risk-management guidelines which attempt to
balance the beneﬁts of pharmaceuticals with their
safety risks of adverse reactions. Third, the evolution
of thinking about drug safety surveillance is that there
should be a multidisciplinary approach to drug safety,
making use of expertise in all relevant disciplines. It
also should apply to the entire life of a drug from
investigation, through new drug application, market-
ing, and withdrawal (if necessary) from the market.
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